KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment (2017 - 2025)

Historic Asset Writedowns and Impairment for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $22.8 million.

  • Amneal Pharmaceuticals' Asset Writedowns and Impairment rose 308.35% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.4 million, marking a year-over-year decrease of 274.8%. This contributed to the annual value of $96.6 million for FY2024, which is 2928.53% up from last year.
  • Amneal Pharmaceuticals' Asset Writedowns and Impairment amounted to $22.8 million in Q3 2025, which was up 308.35% from $23.7 million recorded in Q1 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Asset Writedowns and Impairment registered a high of $32.9 million during Q4 2024, and its lowest value of $3.6 million during Q1 2022.
  • For the 5-year period, Amneal Pharmaceuticals' Asset Writedowns and Impairment averaged around $18.0 million, with its median value being $17.3 million (2023).
  • In the last 5 years, Amneal Pharmaceuticals' Asset Writedowns and Impairment plummeted by 7766.68% in 2022 and then soared by 60441.59% in 2023.
  • Amneal Pharmaceuticals' Asset Writedowns and Impairment (Quarter) stood at $15.4 million in 2021, then skyrocketed by 44.52% to $22.2 million in 2022, then dropped by 18.74% to $18.0 million in 2023, then surged by 82.54% to $32.9 million in 2024, then crashed by 30.8% to $22.8 million in 2025.
  • Its Asset Writedowns and Impairment was $22.8 million in Q3 2025, compared to $23.7 million in Q1 2025 and $32.9 million in Q4 2024.